Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9241 + Avelumab in Advanced Solid Tumors
NCT02994953Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 7
01
Overview
Phase 1, open-label trial of NHS-IL-12 in solid tumor (advanced stage), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC) and 2 more (6 arms), sponsored by EMD Serono. Primary endpoints: Treatment Emergent Adverse Events up to 1311 days, Treatment-Related Adverse Events up to 1311 days and 2 more. Started Jan 2017; status: terminated.
02
Drugs
NHS-IL-12
03
Conditions
solid tumor (advanced stage)urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02994953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994953.